Saturday 17 October 2026
Export RXRX’s income statement to Excel — free account
Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
3.47
0.69
−16.59%
Follow RXRX
| Dec '19 | Jan '20 | Dec '20 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 4 | — | 4 | — | 4 | 3 | 3 | 3 |
Altman Z-Score |
— | — | — | — | 18.18 | 5.64 | 2.20 | 3.32 | 0.69 | 0.37 |
P/S ratio |
111.54 | 111.54 | 111.54 | 111.54 | 283.62 | 298.52 | 33.26 | 46.02 | 31.50 | 24.51 |
Altman Z″-Score (non-manufacturers) |
(0.42) | 3.77 | 5.60 | 7.54 | 9.55 | (0.92) | 1.43 | (2.40) | (0.43) | (1.13) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(23.44) | (23.44) | (23.44) | (23.44) | (47.21) | (49.69) | (29.62) | (27.69) | (16.06) | (39.72) |
Beneish M-Score |
— | — | (1.86) | — | 18.74 | — | — | (4.89) | 7.61 | (1.72) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 5.32 | 5.60 | 2.73 | 4.43 | 1.79 | 1.62 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 5.34 | 5.62 | 2.74 | 5.47 | 3.37 | 2.78 |
EV/Sales |
79.24 | 79.24 | 79.24 | 79.24 | 232.78 | 247.68 | 19.44 | 37.19 | 21.67 | 14.62 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(8.78) | (8.78) | (8.78) | (8.78) | (14.94) | (15.90) | (9.27) | (5.76) | (3.55) | (2.94) |
EV/FCF |
(6.18) | (6.18) | (6.18) | (6.18) | (11.94) | (12.71) | (6.41) | (5.52) | (3.39) | (2.87) |
Quick Ratio |
11.27 | 11.57 | 11.44 | 11.30 | 11.30 | 5.52 | 5.52 | 4.27 | 3.45 | 5.23 |
Current Ratio |
11.43 | 11.67 | 11.53 | 11.46 | 11.46 | 5.68 | 5.68 | 4.70 | 3.81 | 5.50 |
Net Debt/EBITDA |
1.05 | 3.16 | 3.13 | 2.93 | 2.97 | 2.24 | 2.35 | 1.21 | 1.31 | 1.31 |
Debt/Assets |
12.24% | 4.73% | 3.82% | 1.63% | 0.10% | 6.41% | 0.08% | 0.17% | 1.31% | 0.65% |
Debt/Equity |
0.16 | 0.06 | 0.05 | 0.02 | 0.00 | 0.09 | 0.00 | 0.00 | 0.02 | 0.01 |
Asset Turnover |
0.02 | 0.00 | 0.02 | 0.00 | 0.02 | 0.00 | 0.06 | 0.07 | 0.06 | 0.05 |
Operating CF/Net income |
0.92 | 0.52 | 0.52 | 0.85 | 0.85 | 0.35 | 0.35 | 0.88 | 0.77 | 0.58 |
Capex/Depreciation |
(1.57) | 0.00 | (1.71) | 0.00 | (4.73) | 0.00 | (3.18) | (0.51) | (0.47) | (0.10) |
| 49.80% | 0.00% | 52.64% | 0.00% | (110.79%) | 0.00% | (46.56%) | (69.12%) | (61.89%) | (59.54%) | |
| (61.01%) | 0.00% | (43.50%) | 0.00% | (41.03%) | 0.00% | (36.52%) | (48.42%) | (44.11%) | (44.12%) | |
ROIC |
(276.95%) | 0.00% | 0.00% | 0.00% | (448.73%) | 0.00% | 0.00% | (313.71%) | (65.59%) | (103.19%) |
Return on Tangible Assets |
(65.77%) | (31.95%) | (32.31%) | (33.73%) | (33.73%) | (40.52%) | (42.94%) | (76.03%) | (69.42%) | (83.84%) |
Average Days of Receivables |
23.77 | 14.37 | 14.37 | 325.98 | 325.98 | 25.22 | 25.22 | 25.34 | 304.99 | 120.47 |
Research and Development Expense of Revenue |
1,975.38% | 1,598.16% | 1,598.16% | 1,326.07% | 1,329.05% | 389.82% | 390.77% | 541.17% | 534.38% | 636.40% |
Selling, General and Administrative Expense of Revenue |
817.21% | 525.39% | 637.51% | 480.27% | 566.73% | 204.80% | 204.80% | 248.62% | 302.83% | 236.46% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.33 | 0.32 |
Share Based Compensation of Revenue |
59.72% | 0.00% | 108.33% | 0.00% | 145.82% | 0.00% | 70.05% | 120.03% | 138.83% | 148.93% |
Graham Net Nets |
0.23 | 0.23 | 0.23 | 0.23 | 0.16 | 0.15 | 0.27 | 0.12 | 0.16 | 0.26 |
Graham Number |
0.00 | 0.00 | 29.18 | 31.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(14.29%) | (14.29%) | (14.29%) | (14.29%) | (12.85%) | (12.21%) | (18.15%) | (15.70%) | (24.56%) | (36.19%) |
Free Cash Flow Yield |
(11.50%) | (11.50%) | (11.50%) | (11.50%) | (6.87%) | (6.53%) | (9.12%) | (14.64%) | (20.30%) | (20.79%) |
Revenue per Share |
0.11 | 0.02 | 0.18 | 0.06 | 0.08 | 0.23 | 0.23 | 0.21 | 0.21 | 0.17 |
Operating CF per Share |
(2.64) | (0.27) | (2.08) | (0.93) | (1.27) | (0.48) | (0.48) | (1.38) | (1.31) | (0.83) |
Capex per Share |
(0.18) | 0.00 | (0.31) | 0.00 | (0.32) | 0.00 | (0.21) | (0.06) | (0.06) | (0.02) |
Free Cash Flow per Share |
(2.83) | (0.27) | (2.39) | (0.93) | (1.58) | (0.48) | (0.69) | (1.44) | (1.37) | (0.85) |
Cash per Share |
3.48 | 1.61 | 12.13 | 3.04 | 4.13 | 3.14 | 3.14 | 1.90 | 2.18 | 1.67 |
Shareholders Equity per Share |
3.56 | 1.46 | 11.11 | 3.19 | 4.33 | 2.77 | 2.77 | 2.23 | 3.77 | 2.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.56 | 1.46 | 11.11 | 3.19 | 4.33 | 2.77 | 2.77 | 2.23 | 3.77 | 2.53 |
Free Cash Flow |
(60.95) | (45.40) | (52.13) | (158.61) | (198.41) | (83.52) | (120.88) | (300.33) | (376.22) | (380.43) |
Working Capital |
69.71 | 246.38 | 243.34 | 488.06 | 488.06 | 469.55 | 469.55 | 344.97 | 526.80 | 665.14 |
Capital Expenditures |
(3.91) | (6.73) | (6.73) | (39.80) | (39.80) | (37.36) | (37.36) | (12.55) | (17.04) | (8.63) |
Net Current Asset Value |
51.81 | 212.92 | 209.88 | 467.31 | 467.31 | 354.33 | 354.33 | 247.87 | 300.45 | 469.58 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.69 | 0.00 | 1.70 | 0.00 | 3.91 | 0.00 | 0.94 | 0.28 | 0.29 | 0.12 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.17 | 0.15 | 0.13 | 0.13 | 0.16 | 0.13 | 0.28 | 0.26 | 0.81 |
Cash ROIC |
(37.07%) | (8.68%) | (10.07%) | (14.81%) | (18.69%) | (7.72%) | (11.65%) | (34.95%) | (22.78%) | (20.15%) |
Accounts Receivable Turnover |
15.36 | 0.00 | 25.81 | 0.00 | 2.20 | 0.00 | 6.73 | 15.25 | 2.25 | 2.02 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 4.68 | 0.00 | 0.00 | 13.04 | 9.97 | 3.54 | 3.57 |
Inventory Turnover |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.40 | 34.67 | 33.88 | 174.38 | 93.20 |
Days of Inventory on Hand |
— | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.15 | 0.15 | 0.15 | 4.62 | 4.62 | 5.92 | 5.92 | 2.92 | 26.13 | 36.91 |
Average Payables |
1.26 | 1.17 | 1.17 | 1.95 | 1.95 | 3.70 | 3.70 | 4.27 | 12.78 | 19.87 |
Average Assets |
101.43 | 200.01 | 200.01 | 454.47 | 454.47 | 655.82 | 655.82 | 677.49 | 1,051.15 | 1,461.36 |
Average Common Equity |
(124.26) | (165.28) | (165.28) | 168.32 | 168.32 | 514.37 | 514.37 | 474.62 | 749.11 | 1,082.82 |
Columns are period end dates